Skip to Content Skip to Content

Health Sciences

Reset All Filters
2001 Results
Penn Medicine: Investigational Personalized Cellular Therapy Tolerated Well by Patients with Advanced Mesothelioma, Ovarian and Pancreatic Cancers

Penn Medicine: Investigational Personalized Cellular Therapy Tolerated Well by Patients with Advanced Mesothelioma, Ovarian and Pancreatic Cancers

Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers at the Perelman School of Medicine at the University of Pennsylvania.

Steve Graff

New Combination of Immunotherapy Drugs is Safe, Shrinks Tumors in Metastatic Melanoma Patients, Penn Study Finds

New Combination of Immunotherapy Drugs is Safe, Shrinks Tumors in Metastatic Melanoma Patients, Penn Study Finds

Once again, researchers at Penn’s Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

Steve Graff

Immunotherapy Drug Pembrolizumab Shows Early Promise for Mesothelioma Patients, Penn Medicine Researchers Find

Immunotherapy Drug Pembrolizumab Shows Early Promise for Mesothelioma Patients, Penn Medicine Researchers Find

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the Unive

Steve Graff

Penn Medicine Researchers Introduce New Brain Mapping Model Which Could Improve Effectiveness of Transcranial Magnetic Stimulation

Penn Medicine Researchers Introduce New Brain Mapping Model Which Could Improve Effectiveness of Transcranial Magnetic Stimulation

Brain researchers from the Perelman School of Medicine at the University of Pennsylvania have developed a new brain mapping model which could improve the success rate of transcranial magnetic stimulation (TMS) in treating conditions including depression, neuropathic pain, and stroke.

Lee-Ann Donegan

Plasma Ap0A1 Associates with Age at Onset and Motor Severity in Early Parkinson’s Disease Patients, Penn Medicine Researchers Find

Plasma Ap0A1 Associates with Age at Onset and Motor Severity in Early Parkinson’s Disease Patients, Penn Medicine Researchers Find

Building on previous research showing that plasma Apolipoprotein A1 (ApoA1) may be a useful biomarker for Parkinson’s disease, researchers from the Perelman School of Medicine at the University of Pennsylvania have replicated these findings in approximately 1,000 patients from across the world, upholding their

Lee-Ann Donegan

Penn Study Describes First Steps in Basic Biological Process

Penn Study Describes First Steps in Basic Biological Process

Understanding the molecular signals that guide early cells in the embryo to develop into different types of organs provides insight into how tissues regenerate and repair themselves.

Karen Kreeger